|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000253305 |
Summary for PCDHGB6 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000253305 | Gene symbol | PCDHGB6 |
| Gene name | protocadherin gamma subfamily B, 6 | |
| HGNC | 8713 | |
| Entrez ID | 56100 | |
| Gene type | protein_coding | |
| Synonyms | PCDHGB6|PCDH-GAMMA-B6 | |
| UniProtAcc | Q9Y5F9 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for PCDHGB6 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for PCDHGB6 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for PCDHGB6 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| ACC | cg22463553 | chr5:141408937 | CGI:chr5:141407880-141408477 | promoter,exon,CDS,gene body | 5.64e-01 | 7.22e-01 | -2.95e+00 | 3.16e-03 | 1.27e-02 | -1.58e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg03898577 | chr5:141407446 | CGI:chr5:141407880-141408477 | promoter | 3.38e-01 | 1.62e-01 | 3.24e+00 | 1.19e-03 | 2.25e-03 | 1.76e-01 |
| THCA | cg22463553 | chr5:141408937 | CGI:chr5:141407880-141408477 | promoter,exon,CDS,gene body | 5.90e-01 | 4.79e-01 | 2.39e+00 | 1.71e-02 | 2.41e-02 | 1.11e-01 |
| HNSC | cg07613945 | chr5:141407863 | CGI:chr5:141407880-141408477 | promoter | 6.55e-01 | 4.59e-01 | 4.49e+00 | 7.05e-06 | 2.85e-05 | 1.95e-01 |
| HNSC | cg03898577 | chr5:141407446 | CGI:chr5:141407880-141408477 | promoter | 4.07e-01 | 2.63e-01 | 2.37e+00 | 1.79e-02 | 2.10e-02 | 1.44e-01 |
| HNSC | cg22463553 | chr5:141408937 | CGI:chr5:141407880-141408477 | promoter,exon,CDS,gene body | 6.53e-01 | 5.16e-01 | 3.80e+00 | 1.43e-04 | 3.51e-04 | 1.37e-01 |
| LUSC | cg18617005 | chr5:141407937 | CGI:chr5:141407880-141408477 | promoter | 4.63e-01 | 3.94e-02 | 4.26e+00 | 2.02e-05 | 5.26e-04 | 4.23e-01 |
| LUSC | cg18507379 | chr5:141407940 | CGI:chr5:141407880-141408477 | promoter | 4.46e-01 | 2.09e-02 | 4.43e+00 | 9.53e-06 | 5.26e-04 | 4.25e-01 |
| LUSC | cg07613945 | chr5:141407863 | CGI:chr5:141407880-141408477 | promoter | 6.28e-01 | 4.00e-01 | 3.28e+00 | 1.03e-03 | 2.64e-03 | 2.28e-01 |
| LUSC | cg03898577 | chr5:141407446 | CGI:chr5:141407880-141408477 | promoter | 4.15e-01 | 2.19e-01 | 2.05e+00 | 4.00e-02 | 4.16e-02 | 1.96e-01 |
| LUSC | cg22463553 | chr5:141408937 | CGI:chr5:141407880-141408477 | promoter,exon,CDS,gene body | 6.57e-01 | 4.88e-01 | 3.28e+00 | 1.04e-03 | 2.67e-03 | 1.69e-01 |
| LUSC | cg07017875 | chr5:141409680 | CGI:chr5:141409527-141410195 | promoter,exon,CDS,gene body | 5.58e-01 | 4.40e-01 | 3.75e+00 | 1.74e-04 | 9.04e-04 | 1.18e-01 |
| KIRP | cg18507379 | chr5:141407940 | CGI:chr5:141407880-141408477 | promoter | 1.67e-01 | 3.39e-02 | 2.03e+00 | 4.21e-02 | 4.32e-02 | 1.33e-01 |
| ESCA | cg18617005 | chr5:141407937 | CGI:chr5:141407880-141408477 | promoter | 5.38e-01 | 2.62e-01 | 2.06e+00 | 3.89e-02 | 4.64e-02 | 2.76e-01 |
| CHOL | cg18617005 | chr5:141407937 | CGI:chr5:141407880-141408477 | promoter | 4.34e-01 | 4.87e-02 | 3.17e+00 | 1.52e-03 | 1.07e-02 | 3.86e-01 |
| CHOL | cg18507379 | chr5:141407940 | CGI:chr5:141407880-141408477 | promoter | 4.09e-01 | 2.87e-02 | 3.39e+00 | 6.96e-04 | 9.20e-03 | 3.80e-01 |
| CHOL | cg07613945 | chr5:141407863 | CGI:chr5:141407880-141408477 | promoter | 6.38e-01 | 2.11e-01 | 3.10e+00 | 1.96e-03 | 1.07e-02 | 4.28e-01 |
| CHOL | cg07017875 | chr5:141409680 | CGI:chr5:141409527-141410195 | promoter,exon,CDS,gene body | 6.46e-01 | 5.00e-01 | 2.80e+00 | 5.09e-03 | 1.63e-02 | 1.46e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg18617005 | chr5:141407937 | CGI:chr5:141407880-141408477 | promoter | 3.82e-01 | 5.60e-02 | 1.11e+01 | 1.12e-28 | 1.40e-27 | 3.26e-01 |
| BRCA | cg18507379 | chr5:141407940 | CGI:chr5:141407880-141408477 | promoter | 3.66e-01 | 4.23e-02 | 1.10e+01 | 2.86e-28 | 3.40e-27 | 3.23e-01 |
| BRCA | cg07613945 | chr5:141407863 | CGI:chr5:141407880-141408477 | promoter | 6.71e-01 | 3.75e-01 | 8.46e+00 | 2.62e-17 | 1.14e-16 | 2.96e-01 |
| BRCA | cg03898577 | chr5:141407446 | CGI:chr5:141407880-141408477 | promoter | 3.84e-01 | 2.55e-01 | 3.08e+00 | 2.08e-03 | 2.61e-03 | 1.29e-01 |
| BRCA | cg22463553 | chr5:141408937 | CGI:chr5:141407880-141408477 | promoter,exon,CDS,gene body | 6.13e-01 | 4.84e-01 | 7.65e+00 | 2.04e-14 | 7.11e-14 | 1.29e-01 |
| BRCA | cg07017875 | chr5:141409680 | CGI:chr5:141409527-141410195 | promoter,exon,CDS,gene body | 5.40e-01 | 3.96e-01 | 1.13e+01 | 1.45e-29 | 2.01e-28 | 1.44e-01 |
| KIRC | cg07017875 | chr5:141409680 | CGI:chr5:141409527-141410195 | promoter,exon,CDS,gene body | 4.96e-01 | 3.93e-01 | 2.46e+00 | 1.38e-02 | 2.11e-02 | 1.04e-01 |
| LIHC | cg18617005 | chr5:141407937 | CGI:chr5:141407880-141408477 | promoter | 2.25e-01 | 3.97e-02 | 3.57e+00 | 3.58e-04 | 1.02e-03 | 1.86e-01 |
| LIHC | cg18507379 | chr5:141407940 | CGI:chr5:141407880-141408477 | promoter | 2.09e-01 | 2.32e-02 | 4.88e+00 | 1.06e-06 | 1.37e-05 | 1.85e-01 |
| LIHC | cg07613945 | chr5:141407863 | CGI:chr5:141407880-141408477 | promoter | 4.32e-01 | 2.78e-01 | 2.13e+00 | 3.34e-02 | 3.63e-02 | 1.53e-01 |
| LIHC | cg03898577 | chr5:141407446 | CGI:chr5:141407880-141408477 | promoter | 2.93e-01 | 1.51e-01 | 2.17e+00 | 3.00e-02 | 3.33e-02 | 1.43e-01 |
| LIHC | cg22463553 | chr5:141408937 | CGI:chr5:141407880-141408477 | promoter,exon,CDS,gene body | 6.64e-01 | 5.52e-01 | 3.06e+00 | 2.20e-03 | 4.20e-03 | 1.13e-01 |
| LIHC | cg07017875 | chr5:141409680 | CGI:chr5:141409527-141410195 | promoter,exon,CDS,gene body | 6.00e-01 | 4.95e-01 | 3.87e+00 | 1.09e-04 | 4.09e-04 | 1.05e-01 |
| KIRP | cg18617005 | chr5:141407937 | CGI:chr5:141407880-141408477 | promoter | 2.69e-01 | 5.50e-02 | 2.34e+00 | 1.91e-02 | 2.60e-02 | 2.14e-01 |
| KIRP | cg22463553 | chr5:141408937 | CGI:chr5:141407880-141408477 | promoter,exon,CDS,gene body | 6.23e-01 | 5.13e-01 | 2.09e+00 | 3.67e-02 | 4.03e-02 | 1.10e-01 |
Top |
Exon skipping events with PSI in TCGA for PCDHGB6 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for PCDHGB6 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for PCDHGB6 |
| TFs related to PCDHGB6. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CHOL | DMRT3 | PCDHGB6 | 6.44e+00 | 1.82e-02 | 7.23e+00 | 9.82e-01 | Female-biased |
| CHOL | DMRTA1 | PCDHGB6 | 6.19e+00 | 7.82e-03 | 7.19e+00 | 9.92e-01 | Female-biased |
| CHOL | DMRTA2 | PCDHGB6 | 6.38e+00 | 1.03e-02 | 7.31e+00 | 9.89e-01 | Female-biased |
| CHOL | FOXA1 | PCDHGB6 | 4.98e+00 | 1.34e-03 | 6.42e+00 | 9.98e-01 | Female-biased |
| CHOL | FOXA3 | PCDHGB6 | 5.17e+00 | 1.87e-03 | 6.53e+00 | 9.98e-01 | Female-biased |
| CHOL | NKX3-1 | PCDHGB6 | 5.84e+00 | 7.28e-03 | 6.86e+00 | 9.92e-01 | Female-biased |
| CHOL | POU4F1 | PCDHGB6 | 5.85e+00 | 7.49e-03 | 6.86e+00 | 9.92e-01 | Female-biased |
| CHOL | POU5F1 | PCDHGB6 | 5.70e+00 | 1.08e-02 | 6.61e+00 | 9.89e-01 | Female-biased |
| CHOL | ZIM3 | PCDHGB6 | 4.82e+00 | 4.00e-03 | 6.00e+00 | 9.95e-01 | Female-biased |
| DLBC | FOXA1 | PCDHGB6 | 5.55e+00 | 1.49e-02 | 6.35e+00 | 9.85e-01 | Female-biased |
| DLBC | FOXA3 | PCDHGB6 | 5.69e+00 | 1.43e-02 | 6.50e+00 | 9.85e-01 | Female-biased |
| DLBC | RBPJ | PCDHGB6 | 5.07e+00 | 9.90e-01 | 4.10e+00 | 6.77e-03 | Male-biased |
| DLBC | ZIM3 | PCDHGB6 | 5.10e+00 | 1.64e-02 | 5.87e+00 | 9.83e-01 | Female-biased |
| DLBC | ZNF486 | PCDHGB6 | 5.46e+00 | 9.92e-01 | 4.48e+00 | 6.30e-03 | Male-biased |
| DLBC | ZNF605 | PCDHGB6 | 5.00e+00 | 9.92e-01 | 3.95e+00 | 4.95e-03 | Male-biased |
| DLBC | ZNF621 | PCDHGB6 | 5.48e+00 | 9.92e-01 | 4.51e+00 | 6.52e-03 | Male-biased |
| SARC | ZBTB26 | PCDHGB6 | 4.44e+00 | 9.88e-01 | 3.71e+00 | 3.58e-03 | Male-biased |
| SARC | ZNF184 | PCDHGB6 | 5.93e+00 | 9.82e-01 | 5.46e+00 | 1.72e-02 | Male-biased |
| SARC | ZNF785 | PCDHGB6 | 5.03e+00 | 9.83e-01 | 4.52e+00 | 1.38e-02 | Male-biased |
| PCDHGB6 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for PCDHGB6 |
| RBPs related to ES in PCDHGB6. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PCDHGB6 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs13189114 | chr5:145826842:T:A | - | 0.222396724829987 | 0.0183216762625958 | GBM | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7733176 | chr5:133300243:A:G | - | 0.283257062602146 | 0.00391220968542819 | GBM | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of PCDHGB6 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000253305 | PCDHGB6 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| ENSG00000253305 | PCDHGB6 | C0678222 | Breast Carcinoma | 1 | CTD_human |
| ENSG00000253305 | PCDHGB6 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| ENSG00000253305 | PCDHGB6 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| ENSG00000253305 | PCDHGB6 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
